PTL联合ZD55-TRAIL对肝癌细胞Hep3B生长抑制的研究
Enhancement of the Growth Inhibiting Effect to Liver Tumor Cell Hep3B by Combining Parthenolide with ZD55-TRAIL
本研究联合运用NF-kB小分子抑制剂PTL和携带TRAIL的溶瘤腺病毒ZD55-TRAIL在体内杀伤肝癌Hep3B，以评估二者联用的实验疗效。首先用Adeasy系统包装ZD55-TRAIL病毒；分别用MTT、结晶紫和Hoechst33342荧光染色实验检测ZD55-TRAIL、ZD55-TRAIL和PTL联合运用对肝癌细胞株Hep3B和正常肝细胞QSG-7701的增殖抑制作用。结果表明：10 MOI ZD55-TRAIL联合PTL处理72 h后，Hep3B细胞的存活率仅为44%，且对QSG-7701细胞无明显损伤，而10 MOI 的ZD55-TRAIL和PTL分别单独处理后细胞的存活率为70%和66%；结晶紫实验及Hoechst33342染色结果表明联合处理组的Hep3B细胞凋亡特征更加明显。溶瘤腺病毒ZD55-TRAIL联合PTL在体外对肝癌细胞Hep3B细胞具有显著的杀伤性，而对QSG-7701细胞无明显毒副作用。
his study aimed at studying the anti-tumor effect in hepatocarcinoma cell Hep3B by combining Parthenolide with ZD55-TRAIL. The experiment was constructed oncolytic adenovirus ZD55-TRAIL by Adeasy systerm; then, MTT, crystal violet and Hoechst33342 staining assay were used to assessed the growth inhibition effects of single or combination therapy on liver tumor cell Hep3B and human normal cell QSG-7701. The results shown that 10 MOI ZD55-TRAIL combining with PTL treated cell for 72 h, Hep3B cell's survival rate is only 44%, and no significant damage to the QSG-7701 cells, while ZD55-TRAIL and PTL 10 MOI separately treated cell, the survive rate is 70% and 66% respectivelt; the crystal violet the experiment and Hoechst33342 staining results showed that the combined treatment group Hep3B apoptotic features more obviouly. Oncolytic adenovirus ZD55-TRAIL joint PTL significant destruction in vitro on hepatoma cells Hep3B cells, no significant side effects QSG-7701 cells.
吴丽琴、郭科妮、李晓艳、陈侃、杨新燕、马晖、潘强
肿瘤学基础医学药学
小白菊内酯ZD55-TRAIL肝癌
ParthenolideZD55-TRAILHepatoma carcinoma cell
吴丽琴,郭科妮,李晓艳,陈侃,杨新燕,马晖,潘强.PTL联合ZD55-TRAIL对肝癌细胞Hep3B生长抑制的研究[EB/OL].(2012-12-31)[2025-08-23].http://www.paper.edu.cn/releasepaper/content/201212-1189.点此复制
评论